Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "IP"

11174 News Found

CORONA Remedies receives EU-GMP certification for hormone facility
News | June 02, 2026

CORONA Remedies receives EU-GMP certification for hormone facility

Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets


Marksans Pharma to acquire Netherlands-based QliniQ
News | June 02, 2026

Marksans Pharma to acquire Netherlands-based QliniQ

Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets


FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
Drug Approval | June 02, 2026

FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG

First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death


Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial
Clinical Trials | June 02, 2026

Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial

An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary


CellCarta and Leica Biosystems expand push to streamline precision medicine development
News | June 02, 2026

CellCarta and Leica Biosystems expand push to streamline precision medicine development

The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments


BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
Clinical Trials | June 02, 2026

BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial

The safety profile was described as manageable, though not without notable toxicities


Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
Clinical Trials | June 02, 2026

Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial

The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)


Ebola vax on the anvil?
News | June 02, 2026

Ebola vax on the anvil?

CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate


Yoginii partners with Panacea Biotec to expand wellness portfolio
Healthcare | June 02, 2026

Yoginii partners with Panacea Biotec to expand wellness portfolio

Collaboration brings Staart Prime, ChilRun and NikoMom products to Yoginii’s platform, strengthening its family-focused wellness ecosystem and supporting women through motherhood and family care


M|O|C Cancer Care’s research gains global recognition at ASCO 2026
Healthcare | June 02, 2026

M|O|C Cancer Care’s research gains global recognition at ASCO 2026

The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care